A Study of Subcutaneous KY1005 in Healthy Volunteers
Status:
Completed
Trial end date:
2020-11-30
Target enrollment:
Participant gender:
Summary
Single centre, open-label, single dose, parallel group study to investigate the PK, safety
and tolerability of KY1005 after subcutaneous (s.c.) and intravenous (i.v.) administration,
with i.v. KY1005 as a reference treatment.